Ludovic Saba is a second-year internal medicine resident at UT Southwestern Medical Center in Dallas, TX. He is interested in pursuing a fellowship in gastroenterology and hepatology. His research focuses on metabolic dysfunction-associated steatotic liver disease (MASLD), alcoholic liver disease, and healthcare disparities. Prior to residency, Dr. Saba completed two years of clinical outcomes research at the Cleveland Clinic Florida.

I am a consultant in Hepatology and Professor of Practice in Metabolic Liver Diseases at Imperial College London. My area of expertise, includes MASLD.

Dr. Gunn bridges MASH clinical trials with communities in dire need, and has authored numerous peer-reviewed journal articles. She trained at the University of Florida College of Medicine and completed fellowships in gastroenterology and hepatology. Dr. Gunn earned the rank of U.S. Air Force Major and was Chief of Gastroenterology at Eglin Air Force Base in Florida. She founded Impact Research Institute, has taught at Texas A&M and Dell College of Medicine at UT Austin, and is an adjunct faculty member at Baylor University. Dr.

I am the Director of the Liver Research Program at the University of Illinois Chicago. I am actively involved in the Center for Alcohol Research, in the T32 Training Grants from the Cancer Center and the Department of Endocrinology, and in mentoring Graduate students and Postdoctoral fellows. In addition, I hold leadership roles at the American Association for the Studies of Liver Diseases (Steering Committee, Liver Fibrosis SIG) and the International Society for the Hepatic Sinusoid Research (2022-2024 President-Elect). <br>During my Postdoctoral training in Dr.

I am an Associate Professor at University of Kansas Medical Center. My research focuses on epigenetic changes in the liver induced by exposure to alcohol and their role in disease progression and resolution.

I am a physician-scientist at Yale University with a research interest in alcohol-associated liver disease. Our lab studies the pathogenesis of alcohol-associated hepatitis and the ways of liver resident cells interact with immune cells.

Daniel Legg is the U.S. Early Asset Lead for the CardioRenal and Metabolic therapeutic area and Clinical Development Lead for liver disease at Boehringer Ingelheim. He is passionate about advancing science to address unmet medical needs and is honored to share insights on early asset development and clinical strategy at AASLD.

Monica Lizarraga is Director of Patient Advocacy at Madrigal Pharmaceuticals, Inc.